AL
ALX Oncology Holdings Inc.
ALXO · NASDAQ
$1.30 -6.47% (-$0.09)
1M -33.17%
Market Cap $174.9M
P/E Ratio -
Div. Yield -
ROE 90.30%
Bulios Fair Price
$1.18
9.2% downside
Current Price
$1.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ALXO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 1.28x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 53.80%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 56.53%
ROE 90.30%
ROA 50.30%
Debt
69 /100
Low Debt/Equity 0.07x
Current ratio 9.71x
Int. coverage -56.49x
Stability
47 /100
Moderate Beta 0.40x
EPS volatility 30.18%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALXO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jason Lettmann
Employees
48
Headquarters
South San Francisco
Upcoming events
06 NOV
Earnings
Upcoming earnings report